Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia
Authors:
O. Hrodek
Published in:
Transfuze Hematol. dnes,18, 2012, No. 1, p. 51.
Category:
Selection of press reports and books
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2012 Issue 1
- Neutralizing Antibodies Against Emicizumab – Detailed Analysis Based on a Case Study
- Position of aPCC in the Treatment of Hemophilia A Complicated by the Development of Inhibitors
- Sport and Physical Activity Benefit Hemophiliacs
- What FVIII Levels Are Ideal for Preventing Bleeding in Hemophilia A?
- Administration of aPCC as a Prevention of Bleeding After Major Cardiac Surgical Procedures
Most read in this issue
- Asymptomatic pituitary macroadenoma oppressing optic chiasm – ‘incidentaloma‘ – identified within diagnostical staging of patient with primary extranodal diffuse large B-cell lymphoma of orbit and paranasal sinuses – a case report
- The role of physical activity in patients suffering from haematological malignancies
- Prevalence of red blood cell and HLA antibodies in multi-transfused haematological patients
- Mobilization of hematopoetic stem cells using plerixafor - experience of the Czech Republic transplantation centers